Bausch Health Ownership
| BHC Stock | USD 8.12 0.23 2.92% |
Shares in Circulation | First Issued 1994-03-31 | Previous Quarter 370.2 M | Current Value 368.4 M | Avarage Shares Outstanding 232.5 M | Quarterly Volatility 108.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Bausch |
Bausch Stock Ownership Analysis
About 71.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.63. Bausch Health Companies recorded a loss per share of 0.48. The entity last dividend was issued on the 10th of November 2010. The firm had 2:1 split on the 16th of October 2000. Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. Bausch Health Companies Inc. is headquartered in Laval, Canada. Bausch Health is traded on New York Stock Exchange in the United States. For more info on Bausch Health Companies please contact Joseph Papa at 514 744 6792 or go to https://www.bauschhealth.com.Besides selling stocks to institutional investors, Bausch Health also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bausch Health's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bausch Health's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bausch Health Quarterly Liabilities And Stockholders Equity |
|
Bausch Health Insider Trades History
About 11.0% of Bausch Health Companies are currently held by insiders. Unlike Bausch Health's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bausch Health's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bausch Health's insider trades
Bausch Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bausch Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bausch Health Companies backward and forwards among themselves. Bausch Health's institutional investor refers to the entity that pools money to purchase Bausch Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Franklin Resources Inc | 2024-09-30 | 5.3 M | Kohlberg Kravis Roberts & Co Lp | 2024-06-30 | 5.2 M | Citadel Advisors Llc | 2024-09-30 | 5.1 M | Arrowstreet Capital Limited Partnership | 2024-06-30 | 4.2 M | Norges Bank | 2024-06-30 | 3.8 M | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 3.3 M | Laurion Capital Management Lp | 2024-09-30 | 3.1 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 3 M | Deutsche Bank Ag | 2024-06-30 | 2.9 M | Icahn Carl C | 2024-09-30 | 34.7 M | Goldentree Asset Management Lp | 2024-09-30 | 29.4 M |
Bausch Health Companies Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bausch Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bausch Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bausch Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bausch Health Outstanding Bonds
Bausch Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bausch Health Companies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bausch bonds can be classified according to their maturity, which is the date when Bausch Health Companies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Bausch Health Corporate Filings
8K | 1st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 31st of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 1st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 20th of September 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bausch Health Companies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bausch Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bausch Health Companies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bausch Health Companies Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.48) | Revenue Per Share 25.794 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0415 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.